NCT01791920View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

262

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
Skin Aging
Interventions
DRUG

Botulinum toxin type A(Botulax®)

Single administration, Day 0, 20 units

DRUG

Botulinum toxin type A(Botox®)

Single administration, Day 0, 20units

Trial Locations (6)

Unknown

Chung-Ang University Hopspital, Seoul

Seoul National University Hospital, Seoul

National Medical Center, Seoul

Eulji General Hospital, Seoul

The catholic university of Korea, Seoul ST. Mary's Hospital, Seoul

Korea University Anam Hospital, Seoul

All Listed Sponsors
lead

Hugel

INDUSTRY

NCT01791920 - To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines | Biotech Hunter | Biotech Hunter